Referenceprogram for angstlidelser hos voksne - Sundhedsstyrelsen

(89) Stocchi F, Nordera G, Jokinen RH, Lepola UM, Hewett K, Bryson H, et al. Efficacy and
tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J.Clin.Psychiatry
2003;64(3):250-258.
(90) Davidson JR, Bose A, Korotzer A, Zheng H. Escitalopram in the treatment of generalized anxiety
disorder: double-blind, placebo controlled, flexible-dose study. Depress.Anxiety 2004;19(4):234-240.
(91) Kapczinski F, Lima MS, Souza JS, Cunha A, Schmitt R. Antidepressants for generalized anxiety
disorder. Cochrane Database Syst.Rev. 2003;(2):CD003592
(92) Rickels K, Rynn M, Iyengar M, Duff D. Remission of generalized anxiety disorder: a review of the
paroxetine clinical trials database. J.Clin.Psychiatry 2006;67(1):41-47.
(93) Mitte K, Noack P, Steil R, Hautzinger M. A meta-analytic review of the efficacy of drug treatment
in generalized anxiety disorder. J.Clin.Psychopharmacol. 2005;25(2):141-150.
(94) Pollack MH, Meoni P, Otto MW, Simon N, Hackett D. Predictors of outcome following
venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of
short- and long-term studies. J.Clin.Psychopharmacol. 2003;23(3):250-259.
(95) Kavoussi R. Pregabalin: From molecule to medicine. Eur.Neuropsychopharmacol. 2006;16 Suppl
2:S128-33. Epub; 2006 Jun 9.:S128-S133.
(96) Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, et al. Pregabalin in
generalized anxiety disorder: A placebo-controlled trial. Am.J.Psychiatry 2003;160(3):533-540.
(97) Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, et al. A
randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients
with generalized anxiety disorder. J.Clin. Psychopharmacol. 2003;23(3):240-249.
(98) Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized
anxiety disorder: Double-blind, placebo-controlled comparison of BID versus TID dosing. J.Clin.
Psychopharmacol. 2005;25(2):151-158.
(99) Katz RJ, DeVeaugh-Geiss J, Landau P. Clomipramine in obsessive-compulsive disorder. Biol.
Psychiatry 1990;28(5):401-414.
(100) McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind,
placebocontrolled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessivecompulsive
disorder. Arch.Gen.Psychiatry 2000;57(8):794-801.
(101) Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for
obsessivecompulsive disorder. J.Clin.Psychopharmacol. 2002;22(3):309-317.
(102) Fineberg NA, Gale TM. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int.
J.Neuropsychopharmacol. 2005;8(1):107-129.
(103) Davidson J, Pearlstein T, Londborg P, Brady KT, Rothbaum B, Bell J, et al. Efficacy of
sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind,
placebocontrolled study. Am.J.Psychiatry 2001;158(12):1974-1981.
12 Referenceprogram for angstlidelser hos voksne